SAU · 4164.SR · SAR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 12:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SAR. Historical prices are not a forecast.
Nahdi Medical Company’s quoted price sits in the lower half of its reported 52-week range, 21.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Nahdi Medical Company’s forward annual dividend is SAR 5.20 per share, paid semi-annual. The forward yield is 5.7% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Nahdi Medical Company’s next earnings report is currently expected on Mar 15, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nahdi Medical Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nahdi Medical Company stands as a prominent pharmaceutical retail chain with operations spanning both the Kingdom of Saudi Arabia and the United Arab Emirates. Its extensive product portfolio encompasses a diverse range of pharmaceutical goods, health and wellness items, maternal and infant care essentials, beauty products, and various fast-moving consumer goods. Beyond retail, Nahdi provides a comprehensive suite of omni-health services, including polyclinics, rapid-care clinics, telemedicine platforms, laboratory facilities, and home healthcare programs. The company is also actively involved in the wholesale and retail distribution of cosmetics, medicines, specialized dietary products, healthy food options, and medical equipment. With approximately 1,151 pharmacies under its management, Nahdi Medical Company was established in 1986 and maintains its headquarters in Jeddah, Saudi Arabia. It operates as a subsidiary under the umbrella of both Alnahdi Holding Company Limited and Saudi Economic and Development Company Limited.
Latest available per-share figures in SAR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 02:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| SAR 2.53B-4.52% vs estimate |
| Q1 2025 | May 7, 2025 | SAR 1.96+31.54% vs estimate | SAR 2.63B+6.76% vs estimate |
|---|
| Q4 2024 | Mar 10, 2025 | SAR 1.210.0% vs estimate | SAR 2.36B-1.17% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SAR 221.50-SAR 1.60 (-0.72%)
Dr. Sulaiman Al Habib Medical Services Group Company’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
SAR 55.20-SAR 0.40 (-0.72%)
Mouwasat Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
SAR 119.90-SAR 2.10 (-1.72%)
Jamjoom Pharmaceuticals Factory Company’s quoted price sits in the lower half of its reported 52-week range, 26.76% below the high.
SAR 64.95-SAR 0.65 (-0.99%)
Dallah Healthcare Company’s quoted price sits in the lower half of its reported 52-week range, 49.09% below the high.
SAR 30.32-SAR 0.06 (-0.2%)
Dr. Soliman Abdul Kader Fakeeh Hospital Co.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
SAR 36.88-SAR 0.42 (-1.13%)
Al-Dawaa Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 43.91% below the high.
SAR 61.20+SAR 0.25 (+0.41%)
Middle East Pharmaceutical Industries Company’s quoted price sits in the lower half of its reported 52-week range, 22.0% below the high.
SAR 20.99SAR 0.00 (0.0%)
Almujtama Alraida Medical Co.’s quoted price sits in the lower half of its reported 52-week range, 33.37% below the high.
